The end of the boom years has been signalled for pharma, with an anticipated dip in growth to just 1.3% to 2015, according to research from Datamonitor. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/pharma_growth_expected_to_slow_979734Tomorrow is the big day – 7 May; UK General Election day. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/undecided_who_to_vote_for_in_the_uk_general_election_971378Post-election jitters have struck pharma after a surprise result for the UK. With Brexit on the horizon and a minority government in charge, has the industry’s optimism been dashed? - Magazine Article - PharmaTimes
by Katrina Megget
www.pharmatimes.com/magazine/2017/pharmatimes_julyaugust_2017/vote_of_confidenceIt’s all change again in the fight for Salix Pharmaceuticals – last week’s $11 billion bid by Endo International has been binned in favour of rival bidder Valeant Pharmaceuticals International, which has put forward a revised $173-a-share offer. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/valeant_counterbids_for_salix_971189UK plans to fast track access to drugs – in some cases up to ten years earlier – are expected to be announced imminently. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/uk_to_launch_early_access_to_drugs_plan_1001654The anticipated positive decision for AstraZeneca’s anticlotting drug Brilinta (ticagrelor) in the USA has not materialised after regulators announced they wanted more information. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/brilinta_decision_delayed_again_981297The swine flu pandemic has been named as the “most ambitious scam and corruption of our time” after pharma has been found to be in bed with the World Health Organisation. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/swine_flu_labelled_a_conspiracy_984175Janssen-Cilag is to appeal the UK decision to restrictaccess to its multiple myeloma drug Velcade (bortezomib). - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/janssen-cilag_appeals_velcade_decision_982529Johnson & Johnson’s Remicade (infliximab) has been shown to control Crohn’s disease more effectively than standard immunomodulator azathioprine, the company says. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/remicade_effective_in_treating_crohns_986658Eli Lilly is the new drug giant to be raked over hot coals for improper marketing of its drugs. - News - PharmaTimes
by Katrina Megget
www.pharmatimes.com/news/lilly_in_dock_over_improper_marketing_983681
